Alector: Bleak Prospects After Alzheimer's Failure
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
The Pharma Letter16h
FDA to hold AdCom on Exelixis’ cabozantinib sBLA
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company ...
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
The Pharma Letter19h
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
Alector price target lowered to $7 from $35 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...